
Individuals with Stage III/IV epithelial ovarian cancer
Individual Recommended to OUHSC for Ovarian Cancer Treatment
Identified as Benign Tumor
1
6 – 8 cycles platinum and taxane chemotherapy
Identified as Platinum Resistant (PFI < 6 months)
2
PLD, paclitaxel, gemcitabine, topotecan, or bevacizumab monotherapy or in combination therapy
4
Identified as Platinum Super Sensitive (PFI > 24 months).
3
Cancer recurrence after 24 months
Platinum-based doublet treatment – carboplatin + PLD / paclitaxel / gemcitabine
5
No cancer recurrence
Surveillance every 6 months
6